Kymera Therapeutics vs Mesoblast
KYMR and MESO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KYMR and MESO compare
Mesoblast grew revenue faster over the last twelve months (599% versus 134% for Kymera Therapeutics).
Mesoblast keeps more of each dollar of sales as profit, with a net margin of −47.8% compared with −342% at Kymera Therapeutics.
Kymera Therapeutics scores higher on the StockData Score (9 against 6 for Mesoblast), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KYMR | MESO |
|---|---|---|
| Size and price | ||
| Market cap | $10.9B | – |
| Share price | $127.57 | $13.27 |
| Change, 1 year | 101% | −15.5% |
| Change, 5 years | 107% | 6.3% |
| Beta (5Y) | 1.91 | 1.50 |
| Employees | 238 | 108 |
| StockData Score | ||
| Total score | 9 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 2 | 2 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 107× | – |
| P/B | 6.7× | – |
| FCF yield | −2.7% | – |
| Fair value | $36.81 | – |
| Margin of safety | −247% | – |
| Growth | ||
| Revenue growth (TTM) | 134% | 599% (better) |
| Revenue growth, 5Y average | 2.9% | 74.5% (better) |
| Profitability | ||
| Gross margin | 0.00% | 86.1% (better) |
| Operating margin | −396% | – |
| Net margin | −342% | −47.8% (better) |
| FCF margin | −283% | −37.1% (better) |
| Return on equity | −27.3% | – |
| Return on invested capital | −59.0% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 11.13 (better) | 2.43 |
| Altman Z-score | 41.65 | – |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 114% | 0.30% |
| Held by insiders | 38.3% | 37.3% |
| Insider net buying, 12 months | −$301M | $37.5M (better) |
| Short interest, % of float | 16.0% | – |
Go deeper
- KYMR stock overview
- KYMR income statement
- KYMR valuation and score
- MESO stock overview
- MESO income statement
- MESO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.